AbbVie is investing $195 million to strengthen its domestic active pharmaceutical ingredient (API) production within the U.S., with the expansion of its manufacturing plant in North Chicago. This development is part of a larger commitment to invest more than $10 billion in U.S. capital for innovation and critical manufacturing capacity enhancement, according to the company.
AbbVie aims to enhance its chemical synthesis capabilities in the country with this new facility, which will support current and future neuroscience, immunology, and oncology medicines’ domestic production.
“Over the next decade, AbbVie will expand production of API, drug product, peptides, and medical devices in the U.S. to support future medical breakthroughs,” says Robert Michael, chairman and CEO. “This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.”
The construction on the new API facility in North Chicago is set to begin this autumn, with the site planned to be fully operational by 2027. This development will enlarge AbbVie’s current manufacturing presence in the U.S. The company creates more than 6,000 jobs across 11 sites and supports many more through its supplier networks, points out a company spokesperson.
Earlier this month Genmab and AbbVie reported that their subcutaneous bispecific antibody, Epkinly (epcoritamab), had met its dual primary endpoints as a second-line combination therapy for relapsed or refractory (r/r) follicular lymphoma (FL).
The post AbbVie Invests $195 Million to Expand North Chicago Manufacturing Facility appeared first on GEN – Genetic Engineering and Biotechnology News.
